IMV Announces CEO Transition
IMV Inc. (Nasdaq:IMV; TSX:IMV) (IMV or the Company), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that Frederic Ors has stepped down as Chief Executive Officer (CEO), effective immediately.
- IMV Inc. (Nasdaq:IMV; TSX:IMV) (IMV or the Company), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that Frederic Ors has stepped down as Chief Executive Officer (CEO), effective immediately.
- The IMV Board has appointed Andrew Hall, the Companys Chief Business Officer, as Interim CEO.
- On behalf of the Board and everyone at IMV, I want to thank Fred for his valuable contributions and years of service to IMV, said Andy Sheldon, Chairman of the IMV Board.
- We appreciate that Andrew has agreed to step into the role of Interim CEO and are confident that this will be a seamless transition as we continue to advance and expand the IMV footprint in oncology.